GlassScriptPhysician profile
Natalia Arango
NPI 1477972750
$6,626.01
in general payments reported to CMS, 2019-2025
32 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $286 · 2021: $374 · 2022: $4,582 · 2023: $431 · 2024: $741 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,588.93 | 2022 | |
| Hologic Sales and Service, LLC | $357.73 | 2020-2024 | Acessa Provu System, Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $282.34 | 2022-2025 | Veozah |
| Coopersurgical, INC. | $274.76 | 2022-2025 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $256.23 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $206.77 | 2022-2025 | |
| Abbvie INC. | $167.02 | 2020-2023 | Lo Loestrin Fe |
| Organon LLC | $156.57 | 2021-2024 | Nexplanon |
| Becton, Dickinson and Company | $146.60 | 2024 | Arista Ah Flexitip |
| Exeltis, USA INC. | $131.65 | 2021-2025 | Slynd |
| Roche Molecular Systems, INC. | $131.42 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $125.00 | 2020 | |
| Roche Diagnostics Corporation | $124.07 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $111.50 | 2020-2024 | Gardasil 9, Gardasil |
| Therapeuticsmd, INC. | $108.18 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $80.51 | 2022-2024 | Bd Onclarity |
| Organogenesis INC. | $41.30 | 2021 | |
| Avion Pharmaceuticals | $36.49 | 2021-2023 | Balcoltra |
| Sanofi-Aventis U.S. LLC | $35.39 | 2024 | |
| Avanos Medical | $34.51 | 2022 | |
| Pfizer INC. | $28.95 | 2023 | |
| Boston Scientific Corporation | $21.98 | 2022 | |
| Davol INC. | $21.68 | 2023 | Arista Ah Flexitip |
| Sumitomo Pharma America, INC. | $21.23 | 2025 | Myfembree |
| Ethicon US, LLC | $20.83 | 2021 | |
| Teleflex LLC | $18.75 | 2022 | |
| Coloplast Corp | $18.53 | 2021 | |
| Millicent US INC | $17.67 | 2024 | Intrarosa, Femring |
| Medtronic, INC. | $17.21 | 2024 | V-Loc 180 |
| Ascend Therapeutics US, LLC | $15.47 | 2021 | |
| Agile Therapeutics, INC. | $15.01 | 2023 | Twirla |
| Lupin INC. | $11.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Arango listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.